Free Trial
NASDAQ:DAWN

Day One Biopharmaceuticals Q2 2025 Earnings Report

Day One Biopharmaceuticals logo
$7.23 +0.02 (+0.28%)
Closing price 04:00 PM Eastern
Extended Trading
$7.25 +0.02 (+0.28%)
As of 07:37 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Day One Biopharmaceuticals EPS Results

Actual EPS
N/A
Consensus EPS
-$0.35
Beat/Miss
N/A
One Year Ago EPS
N/A

Day One Biopharmaceuticals Revenue Results

Actual Revenue
N/A
Expected Revenue
$35.55 million
Beat/Miss
N/A
YoY Revenue Growth
N/A

Day One Biopharmaceuticals Announcement Details

Quarter
Q2 2025
Time
After Market Closes
Conference Call Date
Tuesday, August 5, 2025
Conference Call Time
4:30PM ET

Conference Call Resources

Day One Biopharmaceuticals Earnings Headlines

Invest where Wall Street isn’t looking—yet
Some investors quietly turn a few thousand dollars into hundreds of thousands—before a company ever goes public. Sure… some of that is luck. But it’s not dumb luck. It’s knowing where to look, and even more importantly, which deals to avoid.
See More Day One Biopharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Day One Biopharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Day One Biopharmaceuticals and other key companies, straight to your email.

About Day One Biopharmaceuticals

Day One Biopharmaceuticals (NASDAQ:DAWN), a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

View Day One Biopharmaceuticals Profile

More Earnings Resources from MarketBeat